Antitrust Antitrust

Comment: Teva probe opens new EU antitrust front on long-held grievances

By Lewis Crofts
  • 05 Mar 2021 04:51
  • 05 Mar 2021 04:51
Teva's new EU antitrust probe into its blockbuster multiple sclerosis drug breaks fresh legal ground for the European Commission, seeing it take on patent filing tactics and a suspected campaign to disparage rival drugs.

While national watchdogs have looked into similar conduct before, it’s a first for the EU enforcer and, if

To view the latest version of this document and thousands of others like it, sign-in to MLex or register for a free trial.

Lewis Crofts


Lewis leads MLex's editorial strategy, content direction, quality and development. He has a reputation for breaking stories and providing analysis on complex legal disputes before regulators and courts around the globe. He has also developed MLex's unrivalled coverage of competition policy, litigation, regulation, Brexit and international investigations.

Discover MLex

Stay on top of global regulatory developments


Latest News